Such evaluation may include testing for myeloproliferative neoplasm driver mutations, cytogenetic studies, including Philadelphia chromosome or BCR-ABL assay, and possibly bone marrow examination, especially in patients with anemia, macrocytosis, leukopenia, and / or hepatosplenomegaly.